Moderna Covid-19 vaccine may be ready for full-scale use by early Q2 2020
MODERNA
$106.18
12:59 25/04/24
Moderna's Covid-19 vaccine candidate will not be ready by the 3 November presidential elections in the US, but it could be by the end of that month.
AstraZeneca
12,026.00p
17:14 25/04/24
FTSE 100
8,078.86
17:14 25/04/24
FTSE 350
4,434.34
17:09 25/04/24
FTSE All-Share
4,387.94
16:49 25/04/24
GSK
1,640.50p
16:45 25/04/24
Pharmaceuticals & Biotechnology
22,750.48
17:09 25/04/24
In an interview with the Financial Times, the chief executive of the biotechnology firm, one of the front-runners to develop a Covid-19 vaccine, also said that submission for approval under expedited emergency use authorisation would not be sought before 25 November - at the earliest.
He did not anticipate full-scale public distribution until spring 2021.
"I think a late [first quarter], early [second quarter] approval is a reasonable timeline, based on what we know from our vaccine," Stephane Bancel reportedly told the FT.
-- More to follow --